- Home
- WNEB vs DRUG Comparison
WNEB vs DRUG Comparison
Compare WNEB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- DRUG
- Stock Information
- Founded
- WNEB 1853
- DRUG 2019
- Country
- WNEB United States
- DRUG United States
- Employees
- WNEB N/A
- DRUG N/A
- Industry
- WNEB Savings Institutions
- DRUG Pharmaceuticals and Biotechnology
- Sector
- WNEB Finance
- DRUG Health Care
- Exchange
- WNEB Nasdaq
- DRUG Nasdaq
- Market Cap
- WNEB 195.7M
- DRUG 199.7M
- IPO Year
- WNEB N/A
- DRUG N/A
- Fundamental
- Price
- WNEB $12.39
- DRUG $41.22
- Analyst Decision
- WNEB Buy
- DRUG Strong Buy
- Analyst Count
- WNEB 2
- DRUG 8
- Target Price
- WNEB $11.00
- DRUG $83.60
- AVG Volume (30 Days)
- WNEB 70.5K
- DRUG 49.6K
- Earning Date
- WNEB 10-22-2025
- DRUG 08-11-2025
- Dividend Yield
- WNEB 2.23%
- DRUG N/A
- EPS Growth
- WNEB N/A
- DRUG N/A
- EPS
- WNEB 0.59
- DRUG N/A
- Revenue
- WNEB $76,036,000.00
- DRUG N/A
- Revenue This Year
- WNEB N/A
- DRUG N/A
- Revenue Next Year
- WNEB $7.36
- DRUG N/A
- P/E Ratio
- WNEB $21.31
- DRUG N/A
- Revenue Growth
- WNEB 2.15
- DRUG N/A
- 52 Week Low
- WNEB $7.63
- DRUG $0.94
- 52 Week High
- WNEB $12.60
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- WNEB 73.26
- DRUG 50.06
- Support Level
- WNEB $12.25
- DRUG $41.00
- Resistance Level
- WNEB $12.60
- DRUG $45.00
- Average True Range (ATR)
- WNEB 0.24
- DRUG 3.00
- MACD
- WNEB 0.02
- DRUG -0.76
- Stochastic Oscillator
- WNEB 92.38
- DRUG 9.84
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.